Healthcare of Ontario Pension Plan Trust Fund Trims Stock Position in LivaNova PLC $LIVN

Healthcare of Ontario Pension Plan Trust Fund lessened its stake in LivaNova PLC (NASDAQ:LIVN) by 51.9% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 48,657 shares of the company’s stock after selling 52,588 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund’s holdings in LivaNova were worth $3,093,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of LIVN. UMB Bank n.a. raised its position in LivaNova by 22.6% during the fourth quarter. UMB Bank n.a. now owns 971 shares of the company’s stock valued at $60,000 after acquiring an additional 179 shares in the last quarter. State of Michigan Retirement System boosted its position in LivaNova by 1.5% in the 1st quarter. State of Michigan Retirement System now owns 13,111 shares of the company’s stock worth $833,000 after purchasing an additional 200 shares in the last quarter. Hantz Financial Services Inc. grew its stake in shares of LivaNova by 159.9% during the 4th quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock worth $27,000 after purchasing an additional 267 shares during the period. Parallel Advisors LLC increased its holdings in shares of LivaNova by 28.8% during the 4th quarter. Parallel Advisors LLC now owns 1,266 shares of the company’s stock valued at $78,000 after purchasing an additional 283 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund increased its holdings in shares of LivaNova by 2.7% during the 1st quarter. Oregon Public Employees Retirement Fund now owns 11,250 shares of the company’s stock valued at $715,000 after purchasing an additional 300 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Stock Down 0.5%

Shares of NASDAQ LIVN opened at $81.05 on Friday. The company’s 50-day simple moving average is $78.96 and its 200-day simple moving average is $70.06. LivaNova PLC has a 52-week low of $41.01 and a 52-week high of $85.27. The firm has a market cap of $4.45 billion, a price-to-earnings ratio of 41.56 and a beta of 0.86. The company has a quick ratio of 1.11, a current ratio of 1.33 and a debt-to-equity ratio of 0.24.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.85 by $0.13. The firm had revenue of $362.26 million during the quarter, compared to the consensus estimate of $346.05 million. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. The company’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.88 EPS. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. Equities analysts predict that LivaNova PLC will post 3.73 EPS for the current fiscal year.

Insider Buying and Selling

In other LivaNova news, Director Francesco Bianchi sold 1,800 shares of the stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total transaction of $136,350.00. Following the completion of the transaction, the director owned 7,228 shares of the company’s stock, valued at $547,521. This represents a 19.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.35% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on LIVN. Weiss Ratings raised shares of LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a report on Thursday, May 7th. Mizuho upped their price objective on shares of LivaNova from $90.00 to $95.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. Zacks Research upgraded LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 21st. Freedom Capital upgraded LivaNova to a “hold” rating in a research report on Tuesday, June 30th. Finally, KeyCorp raised their price objective on LivaNova from $83.00 to $92.00 and gave the company an “overweight” rating in a report on Monday, June 22nd. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $81.38.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.